Alliance Global raised the firm’s price target on Verastem (VSTM) to $18 from $16 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 beat. The Avmapki and Fakzynja launch “continues to trend upward, fast,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem: Strong Commercial Uptake and Expanding RAS/MAPK Oncology Pipeline Underpin Buy Rating and $18 Target
- Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks
- Verastem reports Q4 adjusted EPS (48c), consensus (50c)
- Verastem announces upcoming key milestones
- 3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026